Skip to content
Peptigraph home

Semaglutide and Tirzepatide Together: What Is Known

Semaglutide and Tirzepatide taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GLP-1 agonistFDA approved (Ozempic, Wegovy, Rybelsus)SemaglutideFDA-approved GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus); in a 68-week trial in adults with obesity, mean weight change was -14.9% versus -2.4% with placebo.[20]GLP-1 & metabolicGLP-1 / GIP dual agonistFDA approved (Mounjaro, Zepbound)TirzepatideFDA-approved dual GIP and GLP-1 receptor agonist; in a large trial, mean weight change at week 72 was -15.0% on 5-mg and -19.5% on 10-mg weekly doses.[21]GLP-1 & metabolic
Interaction notes

Timing, interactions and safety

Evidence for the combination

  • SURMOUNT-5: head-to-head randomized trial of tirzepatide versus semaglutide in adults with obesity. · PMID 40353578
  • SURPASS-2: head-to-head randomized trial of tirzepatide versus semaglutide 1 mg in type 2 diabetes. · PMID 34170647
  • Observational cohort study comparing weight loss on tirzepatide and semaglutide (not randomized). · PMID 38976257
  • Real-world observational cohort comparing semaglutide with tirzepatide for cardiovascular outcomes (not randomized). · PMID 41491349
  • Claims-data cohort study in HFpEF that includes a head-to-head tirzepatide versus semaglutide comparison (not randomized). · PMID 40886075
Drug interactions named on the FDA label:
  • Zepbound label, Indications and Usage (Limitations of Use; not Section 7): coadministration with any GLP-1 receptor agonist is not recommended. · FDA label
  • Wegovy label, Indications and Usage (Limitations of Use; not Section 7): concomitant use with any other GLP-1 receptor agonist is not recommended. · FDA label
The studies above describe research settings, not a recommendation to combine them. Ask the prescriber who manages both.
Each component

Side by side

Showing 7 of 12 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.

FieldSemaglutideTirzepatide
ClassGLP-1 agonistGLP-1 / GIP dual agonist
Also calledsema, Ozempic, Wegovy, Rybelsus, Wegovy pilltirz, tirze, Mounjaro, Zepbound
FDA statusFDA approved (Ozempic, Wegovy, Rybelsus)FDA approved (Mounjaro, Zepbound)
Half-lifeapproximately 1 weeksubcutaneous · FDA label (Ozempic)approximately 5 dayssubcutaneous · FDA label (Mounjaro)
Human studies we summarised23 human (19 randomized or controlled) of 27 summarised24 human (22 randomized or controlled) of 30 summarised
Typical study doses
Vial sizes sold2 mg, 3 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg
Related tools

Semaglutide vs Tirzepatide

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison

The comparisons all give people one drug, not both

In SURMOUNT-5, adults with obesity and no diabetes were randomised to one drug or the other, each at the maximum tolerated dose, so nobody received the two together.[12]

At week 72 the average weight change was larger on tirzepatide than on semaglutide in that trial.[12]

In SURPASS-2, which enrolled people with type 2 diabetes, HbA1c fell further at every tirzepatide dose than on semaglutide.[14]

A US real-world cohort comparing the two found similar rates of gastrointestinal adverse events between groups. It was observational, so patients were not randomly assigned.[15]

What each label says about using both

Zepbound's label says to avoid pairing it with any GLP-1 receptor agonist, which includes semaglutide.[18]

Wegovy's label says the same in reverse: it is not recommended with another semaglutide product or any other GLP-1 receptor agonist.[19]

Wegovy's label carries a boxed warning: in rodents, semaglutide causes thyroid C-cell tumours, and the human relevance has not been determined.[19]

Zepbound has a matching boxed warning: in rats, tirzepatide causes dose-dependent thyroid C-cell tumours at clinically relevant exposures.[18]

Compounded versions

FDA's page on unapproved GLP-1 drugs notes that compounded semaglutide and tirzepatide are not reviewed by the agency for safety, effectiveness or quality before marketing.[22]

FDA has received adverse event reports that may be related to compounded semaglutide or tirzepatide prescribed at doses above the approved label. Patients reported symptoms including nausea, vomiting, diarrhea, abdominal pain and constipation.[22]

Common questions

Is tirzepatide better than semaglutide?

In the one randomised obesity head-to-head, average weight loss at week 72 was greater with tirzepatide (-20.2%) than semaglutide (-13.7%); the trial was open-label.[12]

Can you take tirzepatide and semaglutide together?

No: the Zepbound label does not recommend combining it with any GLP-1 receptor agonist, and the Wegovy label says the same for other semaglutide products.[18]

Tirzepatide or semaglutide for type 2 diabetes?

SURPASS-2 concluded that, in patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide on HbA1c change at 40 weeks.[14]

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  3. 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  4. 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  5. 5These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  6. 6Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
  7. 7Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
  8. 8Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
  9. 9These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  10. 10Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
  11. 11Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
  12. 12Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
  13. 13PubMed search: (semaglutide[tiab] OR Ozempic[tiab] OR Wegovy[tiab] OR Rybelsus[tiab] OR NN9535[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.The New England journal of medicine · 2021PMID 34170647Accessed 2 Oct 2026
  15. 15Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.JAMA internal medicine · 2024PMID 38976257Accessed 2 Oct 2026
  16. 16Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER).Diabetes, obesity & metabolism · 2026PMID 41491349Accessed 2 Oct 2026
  17. 17Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.JAMA · 2025PMID 40886075Accessed 2 Oct 2026
  18. 18ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  19. 19WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  20. 20Once-Weekly Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2021PMID 33567185Accessed 2 Oct 2026
  21. 21Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
  22. 22Official web pageOfficial web page · web page

Found an error? Report a correction.